Bone cancer treatment ineffective, despite promising laboratory data
November 10, 2008Ewing sarcoma is the second most common type of primary bone cancer seen in children and young adults. Patients with relapsed or refractory Ewing sarcoma have a poor outcome with conventional therapies. Cytarabine decreases the levels of a certain key protein in Ewing sarcoma cells and has demonstrated preclinical activity against Ewing sarcoma cell lines in the laboratory. Treatment of Ewing sarcoma that relapses is difficult. A new study published in Pediatric Blood & Cancer evaluated a phase II clinical trial of a potential new treatment approach for relapsed Ewing sarcoma using cytarabine.
Ten patients were treated. While one patient's tumor stayed stable in size for approximately 4 months while receiving the drug, none of the ten patients had smaller tumors after treatment with cytarabine. This result is disappointing since laboratory studies indicated that cytarabine might be an effective drug for these patients. In addition, these patients with Ewing sarcoma developed lower blood counts than expected from these doses of cytarabine. The fact that the drug was not found to be effective is yet another example in which laboratory data do not always translate into success in treating patients.
"Cytarabine is not an effective agent for patients with Ewing sarcoma and this drug should be used with caution in heavily pretreated patients with solid tumors due to the significant impact of the drug on blood counts," says Steven DuBois, co-author of the study. This study demonstrates the difficulties of extending promising therapeutic targets observed in the laboratory to effective treatments in patients. It also emphasizes the need for more predictive preclinical models.
Source: Wiley
-
Targeting the Ewing sarcoma family of tumors
Jul 01, 2011 |
not rated yet |
0
-
Scientists use genetically altered virus to get tumors to tattle on themselves
May 11, 2011 |
5 / 5 (1) |
0
-
Arsenic agent shuts down two hard-to-treat cancers in animal experiments
Dec 22, 2010 |
not rated yet |
0
-
Genetically reprogrammed HSV given systemically shrinks distant sarcomas
Jul 07, 2010 |
5 / 5 (2) |
0
-
Research findings expected to ease treatment of low neutrophil counts in cancer patients
Mar 10, 2010 |
not rated yet |
0
-
Engineers build first sub-10-nm carbon nanotube transistor
Feb 01, 2012 |
4.9 / 5 (30) |
30
-
Something old, something new: Evolution and the structural divergence of duplicate genes
Jan 31, 2012 |
4.6 / 5 (7) |
1
-
The hidden nanoworld of ice crystals: Revealing the dynamic behavior of quasi-liquid layers
Jan 30, 2012 |
5 / 5 (3) |
1
-
Stock market network reveals investor clustering
Jan 27, 2012 |
3.9 / 5 (23) |
8
-
Of microchemistry and molecules: Electronic microfluidic device synthesizes biocompatible probes
Jan 26, 2012 |
5 / 5 (1) |
0
-
Is Everyday Technology Killing Us?
Feb 08, 2012
-
Exercise and weight loss
Feb 08, 2012
-
Why do we have head aches? Our brains can't feel anything.
Feb 07, 2012
-
"The end of diseases" by David Agus, interview from Daily Show with Jon Stewart
Feb 04, 2012
-
Oncolytic adenovirus
Feb 04, 2012
-
Nutrition label stuffs and diets
Feb 02, 2012
- More from Physics Forums - Medical Sciences
More news stories
Scientists identify most lethal known species of prion protein
Scientists from the Florida campus of The Scripps Research Institute have identified a single prion protein that causes neuronal death similar to that seen in "mad cow" disease, but is at least 10 times more ...
46 minutes ago |
5 / 5 (2) |
0
|
Researchers weigh in on ethics of H5N1 research
(Medical Xpress) -- In a commentary on the biosecurity controversy surrounding publication of bird flu research details, a bioethicist and a vaccine expert at Johns Hopkins reaffirm that "all scientists have an affirmativ ...
13 minutes ago |
not rated yet |
0
|
To perform with less effort, practice beyond perfection
Whether you are an athlete, a musician or a stroke patient learning to walk again, practice can make perfect, but more practice may make you more efficient, according to a surprising new University of Colorado Boulder study.
Medicine & Health / Neuroscience
52 minutes ago |
4 / 5 (4) |
0
|
New prenatal genetic test is much more powerful at detecting fetal abnormalities
A nationwide, federally funded study has found that testing a developing fetus' DNA through chromosomal microarray (CMA) provides more information about potential disorders than does the standard method of prenatal testing, ...
53 minutes ago |
5 / 5 (1) |
0
First prospective clinical trial of adaptive radiotherapy for head and neck cancer patients
Researchers led by a senior investigator at Hofstra-North Shore LIJ School of Medicine and The Feinstein Institute for Medical Research have released initial findings from a first-of-a-kind clinical trial in adaptive radiotherapy ...
just added |
not rated yet |
0
Hydrogen from acidic water: Researchers develop potential low cost alternative to platinum for splitting water
A technique for creating a new molecule that structurally and chemically replicates the active part of the widely used industrial catalyst molybdenite has been developed by researchers with the Lawrence Berkeley ...
Ultraviolet protection molecule in plants yields its secrets
Lying around in the sun all day is hazardous not just for humans but also for plants, which have no means of escape. Ultraviolet (UV) radiation from the sun can damage proteins and DNA inside cells, leading ...
US workers are 'giving away the store,' costing firms billions
Nearly 70 percent of the nation's service employees give away free goods and services from hamburgers to cable TV costing companies billions of dollars a year, according to a groundbreaking study.
Pa. symphony seeks soloist via YouTube contest
(AP) -- Pittsburgh Symphony Orchestra officials insist it's not "American Idol" meets Mozart.
Thomson Reuters posts loss on $3 bn writedown
Thomson Reuters posted a fourth-quarter loss on Thursday as the financial news and information provider took a $3 billion writedown on its financial services business.